• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    CSafe Global Appoints SVP of Technology and Innovation
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Evotec to Build Second Biologics Mfg. Facility in Toulouse

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    TraceLink Introduces Opus Platform

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    Valneva’s Inactivated, Adjuvanted COVID-19 Vax Achieves Positive Data
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Unifying Quality Manufacturing to Drive Speed, Collaboration, and Compliance

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Alcami

    Aphena Pharma Solutions

    Emergent BioSolutions

    Quotient Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Alcami

    PCI Pharma Services

    Emergent BioSolutions

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Biosimilars and Their Future in Medicine

    The first step is understanding what biosimilars actually are

    Related CONTENT
    • Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer
    • Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement
    • CMOs & Biosimilars Mfg. in the U.S.
    • Allergan and Novartis in Clinical Collaboration
    • Ipsen Appoints R&D EVP and CSO
    Ben Locwin, Healthcare Science Advisors06.02.15
    Some great products and services have been done a disservice by being named something that either didn’t conjure a sufficiently-vivid mental picture of what they were or did, or they had mostly accurate lexical names that didn’t have a sticky quality to them, and the market didn’t respond. Unfortunately, the moniker ‘biosimilar’ is somewhere along the spectrum where those in the industry have a concept of what it means, but in practice it has very little meaning to the general public.

    With direct-to-consumer marketing of prescription drugs worth billions of dollars per year in the U.S., most people understand that ‘generic’ refers to a cheaper version of ‘expensive’ drugs; the two names are almost synonymous. When I asked a sample of 12 people—who passed a qualifying test of correctly answering what a generic drug meant—what a biosimilar was, 0 respondents (0%) had a correct understanding, and 3 respondents (25%) hedged a guess that it was something that had a similar effect in different people. This is, from a public health perspective, an interesting take; though biosimilar refers to the similarity of the resultant molecule compared with the original product, this should give a similar effect in vivo. This however is a non sequitur logical fallacy: From Latin “it does not follow” that a similar molecule will necessarily have similar function or efficacy, with similarity (i.e., non-identicality) becoming more possible with larger and more complex molecules. A common example of this is ethyl alcohol that we drink compared with ethylene glycol, which is very toxic. Without knowing much about the molecular conformations, these two molecules look very similar.

    This has become the difficult philosophical regulatory question: therapeutic molecules are produced similarly, how similar is enough? It was once conventional wisdom that biosimilars couldn’t even be produced. It was thought the molecular complexity was just too high that it wasn’t a viable option to pursue. But production and analytical technologies have advanced dramatically in just the past two decades. Interestingly though, while generic drugs have to be chemically identical and show bioequivalence, biosimilars need to have a high degree of similarity to the innovator product and are considered to be biologically and clinically comparable. This leaves many large sources of error variance in our ability to do like-for-like comparisons within the market.

    How Will We Measure?
    In order to bring less-expensive therapies to those in need, the ethical response should include biosimilars in its toolkit; it doesn’t solve every problem, but it should certainly not be eliminated from consideration. However, if we look at side effect profiles between the innovator product and its biosimilar, what do we do when (not if) we detect differences? What if, over hundreds or thousands of patient-years of exposure, the number-needed-to-treat (NNT) or number-needed-to-harm (NNH) are different between the platform therapy and its biosimilar? These data will manifest soon, and being able to respond intelligently to the questions is simply prudent, smart business, and good pragmatic science. How different does different have to be before we send alert signals?

    Regulatory Track Record: It Has to Start Somewhere
    We have just entered a disruptive era in medicines regulation—the first FDA-approved biosimilar, Zarxio (Novartis), received clearance on March 5. This is a biosimilar of Amgen’s Neupogen. Much of the industry is waiting for this regulatory track record to be built-up so that further approvals can come more quickly. This is the same sort of regulatory paradigm as that facing plant-based antibody production, where therapeutic antibodies are produced within plant cells. The first plant-based recombinant therapeutic protein, Elelyso, was approved in 2012. The lack of a prior regulatory track record, in a market dominated by a long line of successes in mammalian cells, has kept funding capital and prospective therapies from plant cells relatively modest.

    Biosimilars are currently an average of about one-third less expensive than their platform biologics where they are already available. Similar with the pricing structure of generics relative to brand-name drugs, this ratio could become something more like 90%+ less expensive in coming years.

    So as it is with biosimilars being, well, “similar”, the strategic posture will need to be one of deciding how much signal is different enough to do something about or leave alone. Additionally, there’s a great deal of value in revisiting the ethical gray space of monitoring safety and adverse events, but doing it in the context of being able to reach a broader population of patients potentially in need of lower-cost therapies. 


    Ben Locwin
    Healthcare Science Advisors

    Ben Locwin, PhD, MBA, MS writes the Clinically Speaking column for Contract Pharma and is an author of a wide variety of scientific articles for books and magazines, as well as an acclaimed speaker. He also provides advisement to many organizations and boards for a range of healthcare, clinical, and patient concerns.
    Related Searches
    • Pharma
    • Development
    • Biosimilars
    • contract pharma
    Suggested For You
    Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer
    Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    Allergan and Novartis in Clinical Collaboration Allergan and Novartis in Clinical Collaboration
    Ipsen Appoints R&D EVP and CSO Ipsen Appoints R&D EVP and CSO
    Ipsen Appoints R&D EVP and CSO  Ipsen Appoints R&D EVP and CSO
    Quality Risk Management Quality Risk Management
    Genmab Appoints CDO Genmab Appoints CDO
    Biosimilars Outsourcing and Capacity Biosimilars Outsourcing and Capacity
    Injectables: The New Oral? Injectables: The New Oral?
    Vaccine Production Is Only Half of Our Due Diligence Vaccine Production Is Only Half of Our Due Diligence
    2015 in Review: 6 Key Trends Affecting CMOs 2015 in Review: 6 Key Trends Affecting CMOs
    API and Intermediate Outsourcing Trends API and Intermediate Outsourcing Trends
    Growth of Biosimilars: Implications for Safety and Risk Management Growth of Biosimilars: Implications for Safety and Risk Management
    Contracting and Outsourcing Contracting and Outsourcing

    Related Columns

    • Biosimilars
      The Bioprocessing Trek

      The Bioprocessing Trek

      Biosimilars are the next speed-bump for CMOs
      Emil W. Ciurczak, DoraMaxx Consulting 09.16.19

    • Biosimilars
      Know the Challenges of  Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best practices for a competitive market
      Jerry Martin and Michiel Ultee 09.06.17

    • Biosimilars
      Indian Generic Firms  Expand Biosimilar Portfolios

      Indian Generic Firms Expand Biosimilar Portfolios

      With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India
      S. Harachand, Contributing Editor 05.09.17


    • Biosimilars
      CMOs & Biosimilars Mfg. in the U.S.

      CMOs & Biosimilars Mfg. in the U.S.

      Biosimilars are moving from novel opportunity to mainstream product
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17

    • Biosimilars

      Biosimilars Update

      Fulfilling a dire need, but at what (human) cost?
      Ben Locwin, Contributing Editor 04.03.17

    • Biosimilars | Process Development

      Contract Manufacturing Budget Trends

      Study shows where the money is, and isn’t, flowing
      Eric S. Langer, BioPlan Associates 07.12.16


    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16

    • Biosimilars | Clinical Trials

      Outsourced Pharma Services: 2015 Review & 2016 Outlook

      ...
      Chad Moore, Leerink Partners 01.28.16

    • APIs | Biosimilars | Clinical Trials | Process Development | Vials

      2015 in Review: 6 Key Trends Affecting CMOs

      A look at major CMO trends ranging from budgets to growth opportunities
      Eric S. Langer, BioPlan Associates 11.17.15


    • APIs | Biosimilars

      API and Intermediate Outsourcing Trends

      One thing’s for sure, when it comes to pharma trends there is no definitive trend
      Ben Locwin, Healthcare Science Advisors 10.07.15

    • Biosimilars | Fill/Finish | QA/QC

      CMOs Are Willing to Pay for More Innovation

      Downstream improvements top the list
      Eric S. Langer, BioPlan Associates 09.11.15

    • Analytical Services | APIs | Bioanalytical Services | Biosimilars | Chemistry | Clinical Trials | Excipients | GMPs/GCPs | Laboratory Testing | Microbiology | QA/QC | R&D | Regulatory Affairs | Supply Chain | Toxicology | Validation

      Inventas vitam iuvat excoluisse per artes (Let us improve life through science and art)

      But Qui bono? (Who benefits?)
      Emil W. Ciurczak, DoraMaxx Consulting 07.14.15


    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    • Biosimilars | Methods Development | Process Development | Supply Chain | Validation

      CMOs Demanding Easier-to-Integrate Single-use Devices

      Disposables’ implementation and integration critical; suppliers being put on notice
      Jean-Claude Lupis and Eric S. Langer, BioPlan Associates 05.06.15

    • APIs | Biosimilars | Process Development | Supply Chain

      Biosimilars Improving Efficiency, Cost for All Biologics

      ...
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.01.15

    Trending
    • Franco Negron Named CEO Of ApiJect Systems America
    • Obituary Notice: Russell “Russ” Haines
    • Resilience Acquires Ology Bioservices
    • Johnson & Johnson 1Q Results
    • RDIF, Hualan Ink COVID-19 Vaccine Deal
    Breaking News
    • Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    • KemPharm Receives $10M Milestone for FDA Approval of Azstarys
    • Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax
    • Syneos, Medable Partner for New Decentralized Capabilities
    • CSafe Global Appoints SVP of Technology and Innovation
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ashland Supports the Nature Conservancy Forest Restoration Effort to Help Plant a Billion Trees
    Martin Bauer Announces Installation of Agile Filling System at Bethlehem, PA Facility
    PepsiCo and Ingredion Begin Pilot Partnership with Soil and Water Outcomes Fund
    Coatings World

    Latest Breaking News From Coatings World

    AkzoNobel Shareholders Approve Final Dividend at Annual General Meeting
    Sustainable Plastics Will Make Up More Than 15% of Production by 2030
    Axalta Coating Systems Announces $625 Million Increase to Share Repurchase Program Authorization
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Getinge Receives FDA Clearance for Multiple Products
    Study Shows Benefits of CCHD Screening Using Masimo SET Pulse Oximetry
    TEAM Technologies Acquires ViruDefense
    Contract Pharma

    Latest Breaking News From Contract Pharma

    RDIF, Minapharm to Make Over 40M Doses of the Sputnik V Vaccine in Egypt
    Bora Pharmaceuticals Completes Health Canada Inspection
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    New Sustainable Jar from APC Packaging
    Qosmedix Launches Corporate Social Responsibility Initiative
    The KDC Difference: A Focus on Sustainable Beauty Solutions for All
    Happi

    Latest Breaking News From Happi

    Multi-Purpose Sustainable 'Just Add Water' Household Cleaner Expands Cleaning Products
    Kao Launches Oribe in Japan
    Love Beauty and Planet Shares Sustainability Initiatives With Refillable Hair Care at Target
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    SE-DA Invests in Kornit Presto S
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Epson upgrades SurePress demo facility
    Xeikon helps converters navigate toner and inkjet
    Mactac introduces Simply Sustainable initiative
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Savaré Strengthens Technical Support for the Americas
    FiberVisions, Avgol Partner with Polymateria
    High-Tech Conversions Launches Wipes Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Clears Orthofix's 3D-Printed FORZA Titanium TLIF Spacer System
    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Identiv, Ameta International Announce US, Canadian Distribution Partnership
    Adesis Achieves ISO 9001:2015 Certification
    Louis Widmer SA Complies with EU Anti-Counterfeiting Directive with Zebra Technologies’ Solution

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login